Meeting
2015 Genitourinary Cancers Symposium
Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
Authors
Joaquin Mateo
The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Joaquin Mateo , Karim Fizazi , Carmel Jo Pezaro , Yohann Loriot , Niven Mehra , Laurence Albiges , Diletta Bianchini , Andrea Varga , Charles J. Ryan , Daniel Peter Petrylak , Liji Shen , Jenny Zhang , Gerhardt Attard , Johann Sebastian De Bono , Christophe Massard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01511536
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 268)
DOI
10.1200/jco.2015.33.7_suppl.268
Abstract #
268
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
First Author: Cora N. Sternberg
Poster
2020 Genitourinary Cancers Symposium
Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Julie Nicole Graff
Poster
2015 Genitourinary Cancers Symposium
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)
First Author: Ethan M. Basch